Nicotine Vaping
14
4
4
9
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
0.0%
0 terminated out of 14 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
89%
8 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (14)
Examining the Generality of Laboratory-based Findings and Their Moderators in the ITC Study
Testing the Feasibility and Acceptability of Social Media and Digital Therapeutics to Decrease Vaping Behaviors
Promotion and Mitigation Factors Leading to Illegal Tobacco Purchases
Kick-Nic! Youth Quit Vaping App
Comparative Pharmacokinetics and Pharmacodynamics of Synthetic Nicotine
Nicotine Flux, a Potentially Powerful Tool for Regulating Nicotine Delivery From Electronic Cigarettes
Assess the Influence of Nicotine Flux and Nicotine Form on Subjective Effects Related to Dependency
Pilot Study of the YES-CAN! Program to Prevent Youth Nicotine Vaping
A Smartphone Application (ACT on Vaping) for Vaping Cessation in Young Adults
Developing E-liquid Product Standards (Sweet Spot Study)
Comparison of the Substitution Between Different Tobacco/Nicotine Products as a Function of Tobacco-user Type
Nicotine Pharmacokinetics Following Use of the P4M3 Gen 2.0 E-Cigarette Compared to Smoking Cigarettes
Reduced HPHC Exposure in Cigarette Smokers Switching to P4M3 Gen. 2.0 Compared to Continuing Smoking, or Smoking Abstinence
Nicotine and Pavlovian Bias